Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
… thanks for the link. :(
With alll due respect... criticism on SP derived from the idea these folks aren’t marketing...
While product is being sold tested used .... worldwide... if you think staff isn’t working the medical community... getting authorizations to hook patients up ? I think your perception of the task at hand is severely misunderstood.
This isn’t a new toothbrush we’re talking about here .
Oh my :(
And it’s so easy to convince the world that this cartridge full of beads that you hook up to a patient and pump their blood thru actually works and won’t kill them. No... I don’t see much work here .
Timeline...
I read you all … "discussing" the time-line … of Cytosorb and was thinking about similar challenges of non drug type medical "devices".
Since I have one... the Stent came to mind...
http://ptca.org/history_timeline.html
Yea... this stuff aint easy. Relax... I think they are doing fine.
Exploitation of antibiotics... diluting the pool of antibiotic therapies will lead to new therapies to fight sepsis filling the gap to infection control
It is exhausting reading some of this whining....
I suggest you re-visit the Cytosorbents Website and review Exactly what they have accomplished over the past 8 years. Its easier to go to the moon that get a drug or medical device approved in any country in the world. A TON has been done to get this company to the place we are today. The Freakin Stock Market is a whole other story. And you should know that if you are an investor. Yea... I consider this company a startup. I've been in this since 9 cents. As I watch the real progress I know and believe that Cytosorbents is near inflection point. or I would not be an investor. So you either have the kahoonies to hold... or you fold... but you guys that simply log on to bitch about Chan.... wasting your time. Two things I know for sure... Cytosorbents is going to be a winner... and Trump is going to get a second term. Not a bad combination.
https://cytosorbents.com/
https://cytosorbents.com/about/about-us/
https://cytosorbents.com/investor-relations/overview/
Couldn’t disagree more.
With a startup biotech the share holder equity will come with approvals , certification and SOC
I sleep much better having blocked that { insert expletive}
Yea... Good Sport just hit a new low here.
Not necessary. HOWEVER... typical of the left.
Attacking people for where they shop... their weight... where they live (fly over states)
Even the Hat they chose to wear in support of a presidential candidate.
All targets of the elitists left. Sad.
Democratic debate 3 miles from my house... can’t wait !!!!!
Yea... right
Finally someone talking about the stock!!! thanks KID
I think we know the BS posters when we see them... I've blocked most... appreciate real conversation here about CTSO..
I hope Kid is correct... I too made a decent purchase below 5...
Data is accumulating...
like they said in the Jaws movie... "we're going to need a bigger boat"
More bad stock mkt news... bring in the pooper scooper
I thought ESKAY had left the building????
Such bs when you can’t even believe a stock troll
While the politics and markets are raging... the CTSO management team and their partner hospitals are plugging along … doing what has to be done... in the manner in which it has to be done. Yea I agree its like watching paint dry...
No need in complaining...
you either have the tolerance for this... or you don't.
I've been investing in biotech startups for a long time...
We have gone way past the point of a startup IMHO but maturity takes time. I like what I am reading about this column of magical beads.
Eskay just can't read... or doesn't want to …
https://www.cytosorbents.com/wp-content/uploads/2016/03/Website_Cyto_Sepsis_8.2016-Final.pdf
Your sounding VERY much like Pearsbeeeee... U R officially IGNORED.
by the way good...
my large investment in cyto is the only reason I participate in this board. If I moderated … some of these trolls would be dump'd
I already monitor other boards... have attended meetings and had conversations with medical professionals to discuss the science. Some of those conversations have been shared here. I am very long, until I have a reason not to be. IMHO we are all still in line for the big ride. Hard to tell who is a manipulator... and who isn't. I am a 64 year old guy married 42 years... with two successful businesses and a net worth of 2.2 million. some college, some tech school in the 70's Programming. Navy Vet. Designed a software program in 1992 that is still sold today by my tech company. Have a franchise retail group of 4 stores with 22 employees. I have had two cousins die of sepsis. One from a motorcycle accident and the other from a blood infection. My wifes parents.. both of them … have Alzheimer’s. There is cancer in both families. I have watched many friends and family suffer from cancer with no chance of survival. I have also seen first hand the effects of drug addiction and accidental overdose. I have 4 grandchildren..... I watch medical biotech very closely … as much for science as ROI. If the beads are as good as I think they are … based on the current applications and the studies in process.... they indeed could be a game changer. CYTO is like Trump... for some people... they cant do anything right. Even if every single process they are working on was successful... there would still be something wrong. That is that state of the Union as we see it today. Unfortunately I'm stickin around for now. AND Guilty as charged with being P O'd at the trolls for wasting our time here... for whatever the reason. And if they are trying or participating in manipulation of the Sp... Karma is a Be'otch.
No..... I find the real contributions interesting .
I find the trolls distracting. If you don’t want to view my comments, block me or turn the channel.
I’ve been here since 2013.... seen the trolls come and go.
I’m being considerate of moderation so this message gets to you....
Well that was quick ??
Weren’t you leaving?
Ya just can’t stand it can you?
SMH
Elvis has left the building...
Wouldn’t be the first.
Sad.
My sole intention is to offer some balance to the uninformed people, non shareholders, that are motivated to put down the stock for whatever reason... your description of your personality and job etc. is of no consequence here. For all we know you could be a 20 year old barista at Starbucks. I posted a cut and paste from the CytoSorb site with some very positive cardiovascular surgery news. Then I cut and pasted the entire page without edits. Now here is a link to the whole site. Anyone who is invested should go here once a week to see what’s new. This company is very busy. They are not wasting anyone’s time.
https://cytosorbents.com/cytosorbents-highlights-recent-published-studies-on-cytosorb/
They are a publicly traded company. You think they are going to publish lies?
If you sold your shares... (I’m not convinced you had any in the first place) do us all a favor and move on.
The last thing we need is another uniformed amateur giving us advice on our investments. I have a licensed Investment Professional for that.
I’m suppressing the personal attacking here even though my reputation and investment has been called into question by you. My first buy was at 9 cents. Been here awhile.
Here ya go... the whole tamale buddy. Not that it’s not on their website for all to read. I hold 50,000 shares after add at recent lows. I’ve sold significant percentages and re aquired several times.
If I were you I’d stick to blue chips and Dragnet Reruns... less stress. And real bud in a vaporizer pipe is better anyway.
HIGHLIGHTS RECENT PUBLISHED STUDIES ON CYTOSORB
MONMOUTH JUNCTION, N.J., Aug. 28, 2019 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights recent published studies on CytoSorb in multiple applications.
CytoSorbents Logo. (PRNewsFoto/CytoSorbents)
Improvements in Hemodynamic Stability during Cardiac SurgeryThe company-sponsored U.S. REFRESH 2-AKI pivotal study, designed to support U.S. FDA approval of CytoSorb, is evaluating the intraoperative use of CytoSorb to reduce the severity or incidence of acute kidney injury following complex cardiac surgery including valve replacement surgery and aortic reconstructive surgery with hypothermic cardiac arrest (HCA). The latter is an involved surgery where blood flow to the body, with the exception of the brain, is completely stopped for up to 45 minutes while the body is rapidly cooled to lower metabolism and oxygen usage. This procedure, and the restoration of oxygenated blood flow to the body, often results in a systemic inflammatory response that can lead to intraoperative and postoperative hemodynamic instability that can complicate the surgery and lead to negative outcomes.A large, single center, retrospective study was recently published in 336 patients who had undergone aortic surgery involving hypothermic circulatory arrest (HCA) entitled, “Haemadsorption improves intraoperative haemodynamics and metabolic changes during aortic surgery with hypothermic circulatory arrest“. In the study, 168 patients with CytoSorb hemoadsorption used intraoperatively during cardiopulmonary bypass were matched by propensity score to 168 patients receiving standard therapy without CytoSorb (control). The use of CytoSorb significantly reduced the requirement for artificial blood pressure support using vasopressors (p=0.043), with a more stable acid-base balance and lower lactate levels throughout the procedure. CytoSorb use also significantly decreased the need for transfusion of packed red blood cells (p=0.021) and fresh frozen plasma (p=0.001), but increased the use of prothrombin complex concentrate (p=0.004). A trend to improved 30-day mortality (CytoSorb: 4.8%; Control: 8.8%) was observed but not statistically significant. The authors concluded that the use of CytoSorb in the setting of acute aortic surgery with HCA significantly reduces the need for vasopressors, the amount of transfusion, and improves acid-based balance. Improvements in microcirculation in septic shockAchievement of adequate systemic blood pressure is essential to maintain oxygen delivery and blood flow to vital organs to reduce the risk of organ failure in life-threatening illnesses such as sepsis. In multiple studies, in many different applications, CytoSorb has been used to help stabilize blood pressure and wean patients off of artificial blood pressure support using vasopressors. In addition to maintaining systemic blood pressure, there is an expanding understanding that microcirculation, or blood flow through the fine network of blood vessels that feed individual cells of the organ, is often severely compromised in critical illness, and that restoration of microcirculation is important to maintain or improve organ function.Another piece to the puzzle of how CytoSorb works has been uncovered in one of the first published, prospective, observational pilot studies to evaluate microcirculation in sepsis patients entitled, “Changes in cytokines, haemodynamics and microcirculation in patients with sepsis/septic shock undergoing continuous renal replacement therapy and blood purification with CytoSorb“. Researchers used advanced videomicroscopy techniques in nine patients with sepsis or septic shock in kidney failure on renal replacement therapy treated with CytoSorb to demonstrate a significant increase in the number and density of small vessels with blood flow (p<0.01). This key improvement in microcirculation was associated with a significant improvement in a composite index of global organ function called the Sequential Organ Failure Assessment (SOFA) score (12±3 to 10±1 at 24 hours, p=0.039), and a significant decrease in the cytokine, IL-8, after 24 hours of treatment (p<0.05 versus at 6 hours). Future studies using more than one 24-hour CytoSorb treatment are planned.HLH Guideline RecommendationsHemophagocytic lymphohistiocytosis (HLH) is a deadly and severe hyperinflammatory syndrome that is caused by an overactivation of immune cells. It typically manifests with a sepsis-like syndrome with high fever and rapidly progressive organ failure in the context of a very high cytokine storm and levels of inflammatory biomarkers such as ferritin. The presentation of inherited primary HLH, and secondary HLH triggered by infection or malignancy, is virtually indistinguishable from cytokine release syndrome (CRS) seen in CAR T-cell and other cancer immunotherapies, and macrophage activating syndrome in autoimmune diseases. In the report, “Recommendations for the management of hemophagocytic lymphohistiocytosis in adults“, current members of the working group “HLH in Adults” of the Histiocyte Society published guideline recommendations based on expert opinion supported by the best available evidence from studies supporting the individual statements on the treatment of HLH. Citing specific case evidence on the CytoSorb extracorporeal cytokine adsorber in the guidelines on salvage treatment of relapsed and refractory HLH, authors state, “the use of cytokine adsorption columns may aid in rescuing critically ill patients from a deleterious cytokine storm.” This represents one of the first examples of CytoSorb being included into medical practice guidelines.SummaryDr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents stated, “The body of published evidence on the use of CytoSorb in life-threatening illnesses in critical care and cardiac surgery continues to grow. These conditions are often so physiologically complex with such high variability between patients, that despite decades of clinical studies by other companies that have failed, they have defied treatment. Because of this, one in three patients will often die, despite the best supportive medical care, and those that survive are often dead or back in the hospital in the following year. The expanding library of approximately 125 different published papers by independent researchers using CytoSorb continues to highlight the benefit to patients, and that the broad-spectrum activity of CytoSorb is uniquely different. We remain committed to conducting the clinical studies that will make CytoSorb a standard of care in many different applications worldwide.”About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to reduce inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents is conducting its pivotal REFRESH 2-AKI trial – a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury. CytoSorb® has been used in more than 67,000 human treatments to date.CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly $26 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.Forward-Looking StatementsThis press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 7, 2019, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. Please Click to Follow Us on Facebook and TwitterCytosorbents Contact:
Amy Vogel
Investor Relations
(732) 398-5394
avogel@cytosorbents.com Investor Relations Contact:
Jeremy Feffer
LifeSci Advisors
917-749-1494
jeremy@lifesciadvisors.com U.S. Public Relations Contact:
Joshua Berkman
Rubenstein Public Relations
212-805-3055
jberkman@rubensteinpr.com
SOURCE CytoSorbents Corporation
Post navigation
? CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022 CytoSorbents to Present at the H.C. Wainwright 21st Annual Global Investment Conference ?
Home Contact
If the investor wants to read the whole report... they can.
I didn’t conveniently leave anything out.
I’m not a person to intentionally mislead anyone.
If anyone is investing in CTSO and is relying on this board for advice...
They are doing themselves a disservice
Fantom?????? isn't that what I asked you to do?
Game players …… SMH
Fantom
"It was fact based sarcasm. Do I need to explain it? "
Hadto
"What the hell are you talking about??
Dam man.... English please "
What the hell are you talking about??
Dam man.... English please
Yea.. nothing going on at Cytosorbents….
A large, single center, retrospective study was recently published in 336 patients who had undergone aortic surgery involving hypothermic circulatory arrest (HCA) entitled, “Haemadsorption improves intraoperative haemodynamics and metabolic changes during aortic surgery with hypothermic circulatory arrest“. In the study, 168 patients with CytoSorb hemoadsorption used intraoperatively during cardiopulmonary bypass were matched by propensity score to 168 patients receiving standard therapy without CytoSorb (control). The use of CytoSorb significantly reduced the requirement for artificial blood pressure support using vasopressors (p=0.043), with a more stable acid-base balance and lower lactate levels throughout the procedure. CytoSorb use also significantly decreased the need for transfusion of packed red blood cells (p=0.021) and fresh frozen plasma (p=0.001), but increased the use of prothrombin complex concentrate (p=0.004). A trend to improved 30-day mortality (CytoSorb: 4.8%; Control: 8.8%) was observed but not statistically significant. The authors concluded that the use of CytoSorb in the setting of acute aortic surgery with HCA significantly reduces the need for vasopressors, the amount of transfusion, and improves acid-based balance.
Why don’t you guys shadow management and the sales guys for a day and then give us your opinion.
You’re reviewing the movie from watching the trailer. Ever sold anything to a hospital?
Not easy.
The Reach by the Peach....
I believe PeachBreath might sing a different tune if his name or his beloved were in one of Andy’s cases of the week.
That would be a game changer for Mr Tree Fruit.
Please doctor... gimme the Beads!
The Turd is totally delusional!
The man has no freakin idea how difficult a Life Saving medical “products” is to get approved and accepted.
No Freakin Clue.
My analysis of the “Hit Piece “ is mixed. For sure it was a hit piece! The street should be lead accountable for publishing it. Did they gave CTSO a heads up, and opportunity to rebut? No! That’s bs.
I’m sure there are valid true points. I positive there are at best, allegations that are opinion rather than fact. I believe CTSO management should hit back line by line.
The one PR ain’t enough.
I’ve made my call.
Bio... thanks for that.
It’s obvious who has motive here...
admin should flush em
So to speak
Ok I missed vol by half but sp flat.
Why do you guys want to hang mgmt over an obvious Hit Job beyond their control?
Blast “Gordon Gecko” ... not DC. Yea. We were “ Gecko’d “
80,000 shares in 15 min ..... any guesses on numbers at the bell?
I say a half million... flat
Fasten your seat belts sports fans....
Hot off my Alerts in ETrade… geezus.. WTF!!!
CytoSorbents Receives Renewal of CytoSorb(R) CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022
1:54 PM ET 8/15/19 | PR Newswire
MONMOUTH JUNCTION, N.J., Aug. 15, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb(R) blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CytoSorb has received renewal of its European Union CE Mark through May 2024 and ISO 13485:2016 Full Quality Assurance System certification of its manufacturing facility through September 2022.
Mr. Vincent Capponi, Chief Operating Officer of CytoSorbents stated, "I am happy to announce CytoSorbents successfully completed its CE Mark and ISO13485:2016 re-certification audits. These certificates cover CytoSorb and our new manufacturing facility commissioned in June 2018. The success of this renewal of the CE Mark and recent audit is a reflection of CytoSorbents' ongoing commitment to quality. I am very proud of our quality, manufacturing, and research teams that contributed to these accomplishments."
Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents Corporation stated, "We are pleased to have achieved these important milestones, enabling us to continue manufacturing, marketing and selling CytoSorb throughout all of our existing countries, and in future countries that accept E.U. regulatory approval through the next renewals. CytoSorb continues to grow in adoption and usage throughout the world, and is generating an increasing amount of new positive clinical data, because it is helping physicians stabilize and regain control of their patients in a wide variety of critical illnesses and complications of cardiac surgery. The patients that CytoSorb treats are among the sickest of the sick in the hospital, where no therapy in the past has been able to impact poor overall outcomes. We, our partners, and the growing number of physicians and healthcare workers around the world, have seen how CytoSorb is different, and are proud that CytoSorb has been used in more than 67,000 treatments, up from 46,000 a year ago, as a powerful therapy to help save lives. We are on a mission to make this therapy available to the tens of millions of patients each year who are dying or being disabled from life-threatening illnesses."
Dr. Chan continued, "Having completed our strongest quarter ever in CytoSorb sales with an expansion of our blended product gross margins by 200 basis points to 76%, and with a solid cash position of approximately $20 million, we are confident in even stronger growth ahead, driven by the addition of many talented new people in sales, marketing, clinical, manufacturing, and quality, many of whom will start over the next several months. We are convinced that we are in the right place and time, with the right people, and the right product to drive further success of our company, and we are grateful to all of the people who have helped to support this company and make this therapy a reality."
https://www.etrade.wallst.com/v1/stocks/news/search_results.asp?docKey=1-SN20190815015047-5A69N8OEB16GSDN1SSVT2JV3UQ&DMSourceID=PR%20Newswire&Source=PR%20Newswire&docDate=2019-08-15%2017:54:00&headline=CytoSorbents%20Receives%20Renewal%20of%20CytoSorb%28R%29%20CE%20Mark%20Through%20May%202024%20and%20Annual%20ISO%2013485%3A2016%20Certification%20Through%20September%202022&refSymbols=US;CTSO
So if mako is such a skunk why the street publish?
Would seem like the salacious trump dossier syndrome...
Is there no recourse other than for CTSO lawyers to debunk line by line?
Anything else supports their claims unfortunately
This my friends is going to leave a mark ??
SMH
Well... Chan has to address this... quickly.
You only looze when u sell it!